Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 4/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 3/20 | 0.49 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2969565 | 1.00 | BCHE (0.53) | BCHEIMPDH2IMPDH1PTPN1POLB | |
| SCHEMBL12368240 | 0.83 | IMPDH2 (0.51) | BCHEIMPDH2IMPDH1 | |
| SCHEMBL13202467 | 0.82 | BCHE (0.53) | BCHEIMPDH2IMPDH1 | |
| SCHEMBL14518603 | 0.82 | IMPDH2 (0.52) | BCHEIMPDH2IMPDH1ALDH1A1KDM4E | |
| SCHEMBL19747754 | 0.81 | BCHE (0.59) | BCHEIMPDH2IMPDH1 | |
| SCHEMBL12368238 | 0.81 | IMPDH2 (0.49) | BCHEIMPDH2IMPDH1 | |
| SCHEMBL6588176 | 0.81 | MEN1 (0.52) | POLBALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL4947755 | 0.81 | MEN1 (0.52) | POLBALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL14543430 | 0.79 | IMPDH2 (0.50) | BCHEIMPDH2IMPDH1 | |
| SCHEMBL6893614 | 0.75 | IMPDH2 (0.44) | BCHEIMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7777048-B2 | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777048-B2 | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-17 | — | — | US | disclosed |
| US-7777048-B2 | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-17 | — | — | US | disclosed |
| US-20090221835-A1 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-03 | — | — | US | disclosed |
| US-20090221835-A1 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-03 | — | — | US | disclosed |
| US-20090221835-A1 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2009-09-03 | — | — | US | disclosed |
| US-7544810-B2 | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544810-B2 | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544810-B2 | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080021222-A1 | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080021222-A1 | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| US-20080021222-A1 | Processes for preparing biaryl ureas and analogs thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-24 | — | — | US | disclosed |
| EP-1879858-A2 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | Vertex Pharmaceuticals, Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006122072-A2 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021222-A1 | Processes for preparing biaryl ureas and analogs thereof | IMPDH1, IMPDH2, UGDH | BCHE 267/4885IMPDH2 2/4885IMPDH1 1/4885 |
| US-20090221835-A1 | PROCESSES FOR PREPARING BIARYL UREAS AND ANALOGS THEREOF | IMPDH1, IMPDH2, UGDH | BCHE 267/4885IMPDH2 2/4885IMPDH1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.